![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PRSS35 |
Gene summary for PRSS35 |
![]() |
Gene information | Species | Human | Gene symbol | PRSS35 | Gene ID | 167681 |
Gene name | serine protease 35 | |
Gene Alias | C6orf158 | |
Cytomap | 6q14.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N3Z0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
167681 | PRSS35 | ATC13 | Human | Thyroid | ATC | 9.49e-85 | 2.49e+00 | 0.34 |
167681 | PRSS35 | ATC5 | Human | Thyroid | ATC | 1.35e-88 | 2.64e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRSS35 | SNV | Missense_Mutation | c.992C>A | p.Ser331Tyr | p.S331Y | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
PRSS35 | SNV | Missense_Mutation | c.1103N>T | p.Ala368Val | p.A368V | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
PRSS35 | SNV | Missense_Mutation | rs746577637 | c.193N>A | p.Glu65Lys | p.E65K | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PRSS35 | SNV | Missense_Mutation | c.1103N>T | p.Ala368Val | p.A368V | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
PRSS35 | SNV | Missense_Mutation | novel | c.638N>T | p.Gly213Val | p.G213V | Q8N3Z0 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
PRSS35 | SNV | Missense_Mutation | c.872N>C | p.Met291Thr | p.M291T | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
PRSS35 | SNV | Missense_Mutation | novel | c.638N>T | p.Gly213Val | p.G213V | Q8N3Z0 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-BG-A0MQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRSS35 | SNV | Missense_Mutation | rs141429310 | c.779N>T | p.Pro260Leu | p.P260L | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRSS35 | SNV | Missense_Mutation | novel | c.638N>T | p.Gly213Val | p.G213V | Q8N3Z0 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-D1-A0ZP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
PRSS35 | SNV | Missense_Mutation | novel | c.638N>T | p.Gly213Val | p.G213V | Q8N3Z0 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-D1-A0ZU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |